慢性心力衰竭患者血浆H2松弛素的表达

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the expression of endogenous H2 relaxin hormone in chronic heart failure patients, and the relations with NYHA classification, to study its effect on the prognosis of patients with chronic heart failure prediction. Methods: One hundred and forty patients were selected for reseach from July 2012 to September 2012, in the First Affiliated Hospital of Wenzhou Medical University, 109 cases for chronic heart failure group and 31 cases for control group. In the early morning of the first day after admission, patients in each group were exsanguinated in supine, resting status for some venous blood to detect, LDL-cholesterol, hemoglobin, fasting blood glucose, creatinine clearance rate, brain natriuretic peptide (BNP) and so on. ELISA was performed to analyze the plasma concentration of H2RLX, collagen I. In addition, echocardiography inspection was given to estimate left ventricular ejection fraction. Results: ①Plasma H2RLX level of chronic heart failure patients [0.604 (0.419-0.743)] pg/mL was significantly higher than that of control group [0.390 (0.355-0.425)] pg/mL. The difference was statistically significant (P<0.05). ②The tendency as classification of NYHA showed that the plasma level of H2RLX and collagen I both increased in all of heart failure (HF) patients as aggravation of cardiac dysfunction. The difference was statistically significant (P<0.05). ③Plasma level of H2RLX and type I collagen showed significant correlation, there was statistically significant (r=0.889, P<0.001). ④H2RLX levels in chronic heart failure patients could predict the cardiovascular event in one hundred and eighty days. Conclusion: The H2RLX levels elevate in patients with chronic heart failure, which may involve in ventricular fibrosis; H2RLX may help to make preliminary estimation of the severity of chronic heart failure and H2RLX plasma levels may predict the prognosis of cardiovascular events.

Key words： H2 relaxin chronic heart failure fibrosis severity prognosis

Received: 08 January 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Yanyan1
	PAN Jialin2
	CHEN Lingzhi3
	ZHOU Xi1
	ZHENG Gaoshu1
	LIN Jie1
	HUANG Weijian1
	ZHANG Huaiqin1
	ZHOU

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I1/22

[1] Hisaw FL. Experimental relaxation of the pubic ligament of the guinea pig[J]. Exp Biol Med, 1926, 23(8): 661-663
[2] Bani D, Nistri S, Formigli L, et al. Prominent role of relaxin in improving postinfarction heart remodeling[J]. Ann NY Acad Sci, 2009, 1160(1): 269–277.
[3] Teerlink JR, Cotter G, Davison BA, et al. Relaxin in Acute Heart Failure (RELAX-AHF) Investigators Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial [J]. Lancet, 2013, 381(9860): 29-39.
[4] Hocher B, Ziebig R, Krause R, et al. Relaxin is an independent risk factor predicting death in male patients with end-Stage kidney disease[J]. Circulation, 2004, 109(19): 2266-2268.
[5] Dschietzig T, Teichman S, Unemori E, et al. First Clinical Experience with Intravenous Recombinant Human Relaxin in Compensated Heart Failure[J]. Ann NY Acad Sci, 2009, 1160: 387-392.
[6] 杜晓军, 范粉灵, 徐琦. 松弛素在逆转心肌纤维化和主动脉硬化中的作用及其机制[J]. 中国医学前沿杂志, 2011, 3 (5): 24-28.
[7] Debrah DO, Conrad KP, Jeyabalan A, et al. Relaxin increases cardiac output and reduces systemic arterial load inhypertensive rats[J]. Hypertension, 2005, 46(4): 745-750.
[8] Samuel CS, Cendrawan S, Gao XM, et al. Relaxin remodels fibrotic healing following myocardial infarction[J]. Lab Invest, 2011, 91(5): 675-690.
[9] Hudson P, John M, Crawford R, et al. Relaxin gene expression in human ovaries and the predicted structure of a human preprorelaxin by analysis of cDNA clones[J]. EMBO J, 1984, 3(10):2333-2339.
[10] Kupari M, Mikkola TS, Turto H, et al. Is the pregnancy hormone relaxin an important player in human heart failure?[J]. Eur J Heart Fail, 2005, 7(2): 195-198.
[11] Dschietzig T, Richter C, Bartsch C, et al. The pregnancy hormone relaxin is a player in human heart failure[J]. FASEB J, 2001, 15(12): 2187-2195.
[12] Segura AM, Frazier OH, Buja LM. Fibrosis and heart failure [J]. Heart Fail Rev, 2014, 19(2): 173-185.
[13] Mookerjee I, Unemori EN, DU XJ, et al. Relaxin modulates fibroblast function, collagen production, and matrix metalloproteinase-2 expression by cardiac fibroblasts[J]. Ann NY Acad Sci, 2005, 1041: 190-193.
[14] Du XJ, Gao XM, Wang B, et al. Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing β2-adrenergic receptors in the heart[J]. Cardiovasc Res, 2000, 48(3): 448-454.
[15] Chow BSM, Chew EGY, Zhao C, et al. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-Dependent Pathway to Up-Regulate Matrix metalloproteinases: the odditional involvement of iNOS[J]. PLoS One, 2012, 7(8):e42714.
[16] Du XJ, Samuel CS, Gao XM, et al. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype[J]. Cardiovasc Res, 2003, 57(2): 395-404.
[17] Du XJ, Xu Q, Lekgabe E, et al. Reversal of cardiac fibrosis and related dysfunction by relaxin[J]. Ann NY Acad Sci, 2009, 1160: 278-284.